PatientCrossroads to Participate in Cancer Moonshot Summit with Vice President Joe Biden

Share Article

Cites MPS Society and Latin American partnership as examples of joining forces to prevent data silos from impeding medical advances.

“Imagine how much faster we could improve the lives of patients and outsmart cancer if we listen to the voice of patients, aggregate more data and provide safeguarded access to researchers and drug developers.”

PatientCrossroads CEO Kyle Brown is participating in the National Cancer Moonshot Summit at Howard University today. The invitation from Vice President Joe Biden and Jill Biden, Ph.D., recognizes PatientCrossroads’ innovative platform and ability to form patient-centered collaborations with advocacy groups, researchers and drug developers to optimize the search for new treatments for cancer and other diseases.

The company previewed plans for expanding the groups involved in one of its research-ready patient registries as an example of the mindset needed to find better treatments, faster. A registry started by two advocacy groups for Sanfilippo syndrome (also known as MPS III) now includes 22 national and international advocacy groups and will expand to include all MPS types through a planned collaboration with The National MPS Society. (MPS III is one of the six major forms Mucopolysaccharidosis, a genetic lysosomal storage disease) “We encourage cancer and rare disease advocacy groups to unite in collecting data because it’s the right thing to do for patients. It also gives researchers and drug developers opportunities to spot patterns across larger datasets,” explained Brown.

PatientCrossroads continues to champion projects such as its recently announced partnership spanning 21 Latin American countries to collect medical history and treatment information from more than 125,000 cancer and rare-disease patients.

”Our platform enables individual advocacy groups to build branded research communities, then amplifying their impact by aggregating de-identified patient data with other groups addressing the same or related diseases,” Brown said. “Imagine how much faster we could improve the lives of patients and outsmart cancer if we listen to the voice of patients, aggregate more data and provide safeguarded access to researchers and drug developers.”

PatientCrossroads’ Approach Dovetails With Cancer Moonshot Mission
President Barack Obama, in his 2016 State of the Union address, called on Vice President Biden to lead a new national “Moonshot” initiative to “eliminate cancer as we know it.”

“The Moonshot cannot be achieved by one person, one organization, one discipline or even one collective approach,” Vice President Biden said. “Solving the complexities of cancer will require the formation of new alliances to defy the bounds of innovation and accelerate the prevention, diagnosis, treatment, and—ultimately—a cure. It’s going to require millions of Americans speaking up and contributing what they’re able. That’s what the Cancer Moonshot Summit is all about.”

The Cancer Moonshot Summit will be the first time that stakeholders representing all types of cancers will convene under one national charge. The daylong National Cancer Moonshot Summit brings together scientists, oncologists, donors and patients to share new ideas and launch new collaborations. It is aimed at creating action and fostering collaborations around the goals of the Cancer Moonshot.

“Our company mission is perfectly aligned with the goals of the Cancer Moonshot Summit and we are excited to be part of this groundbreaking effort,” Brown said. “Our ability to amplify the voice of patients delivers insights that can’t be found in electronic health records. We believe that making safeguarded data broadly available will be essential to the success of the Cancer Moonshot.”

About PatientCrossroads
Patient Crossroads is a patient-centered data company in Silicon Valley with an innovative business model that optimizes the search for better treatments for diseases. We aggregate and curate data to amplify the voice of patients. Our secure, cloud-based, multilingual platform enables users to conduct targeted studies and quantify value during every phase of drug development and commercialization.

We deliver patient insights faster, and for far less, than traditional registries and CRO organizations. Our approach fosters ongoing patient engagement. We make personalized medicine and pan-disease research possible. Since 2007, we have developed programs for more than 400 diseases through our work with over 100 advocacy groups, NIH, PCORI, biotech and pharma companies. For more information, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Craig Chapman
since: 11/2011
Follow >
Visit website